Combination therapy of the chimeric monoclonal anti-tumor necrosis factor α antibody (infliximab) with methotrexate in patients with rheumatoid arthritis

被引：0
|
作者：
Antoni, C [1 ]
Kalden, JR [1 ]
机构：
[1] Univ Erlangen Nurnberg, Inst Immunol & Rheumatol, Dept Med 3, D-91023 Erlangen, Germany
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 1999年 / 17卷 / 06期
关键词：
infliximab; methotrexate; tumor necrosis factor; combination treatment; rheumatoid arthritis; efficacy; side effects; immunogenecity;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Infliximab, a chimeric anti-TNF alpha antibody, showed in two double-blind placebo-controlled trials efficacy in combination with methotrexate (MTX) inpatients with severe rheumatoid arthritis (RA). Whereas in the first trial low-dose MIX or placebo was compared to infliximab alone and in combination, the second trial compared infliximab to placebo inpatients with active RA despite maximal tolerated MTX treatment. Infliximab showed synergistic effects in combination with MTX. The immunogenicity of infliximab was reduced by the combination. Infliximab in combination with high-dose MTX is effective and safe in long-term treatment up to 54 weeks.
引用
收藏
页码：S73 / S77
页数：5
相关论文
共 50 条
  • [21] The comparative effectiveness of methotrexate and anti-tumor necrosis factor therapy in psoriatic arthritis
    Christopher T. Ritchlin
    Current Rheumatology Reports, 2008, 10 (4) : 295 - 296
  • [22] Therapeutic effects of the anti-tumor necrosis factor monoclonal antibody, infliximab, in four children with refractory juvenile idiopathic arthritis
    Norambuena, X.
    Mallol, J.
    Rios, G.
    Quevedo, F.
    Quezada, A.
    ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2007, 35 (02) : 52 - 56
  • [23] Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis
    Tak, PP
    Taylor, PC
    Breedveld, FC
    Smeets, TJM
    Daha, MR
    Kluin, PM
    Meinders, AE
    Maini, RN
    ARTHRITIS AND RHEUMATISM, 1996, 39 (07): : 1077 - 1081
  • [24] Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α, infliximab
    Schopf, RE
    Aust, H
    Knop, J
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (06) : 886 - 891
  • [25] Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis
    Haerter, G
    Manfras, BJ
    de Jong-Hesse, Y
    Wilts, H
    Mertens, T
    Kern, P
    Schmitt, M
    CLINICAL INFECTIOUS DISEASES, 2004, 39 (09) : E88 - E94
  • [26] Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab
    Brandt, J
    Haibel, H
    Cornely, D
    Golder, W
    Gonzalez, J
    Reddig, J
    Thriene, W
    Sieper, J
    Braun, J
    ARTHRITIS AND RHEUMATISM, 2000, 43 (06): : 1346 - 1352
  • [27] A prospective study of anti-tumor necrosis factor therapy in South African rheumatoid arthritis patients
    Pettipher, Clive
    Rudolph, Riana
    Musenge, Eustasius
    Tikly, Mohammed
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2016, 19 (06) : 594 - 599
  • [28] Anti-Tumor Necrosis Factor-Alpha Therapy and Periodontal Parameters in Patients With Rheumatoid Arthritis
    Mayer, Yaniv
    Balbir-Gurman, Alexandra
    Machtei, Eli E.
    JOURNAL OF PERIODONTOLOGY, 2009, 80 (09) : 1414 - 1420
  • [29] The evaluation of sleep quality and response to anti-tumor necrosis factor α therapy in rheumatoid arthritis patients
    Karatas, Gulsah
    Bal, Ajda
    Yuceege, Melike
    Yalcin, Elif
    Firat, Hikmet
    Dulgeroglu, Deniz
    Karatas, Fatih
    Sahin, Suleyman
    Cakci, Aytul
    Ardic, Sadik
    CLINICAL RHEUMATOLOGY, 2017, 36 (01) : 45 - 50
  • [30] Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis Patients Are Not Associated with Increased Lymphoma Risk
    Wong, A. K.
    Kerkoutian, S.
    Said, J. W.
    Rashidi, H.
    Pullarkat, S. T.
    MODERN PATHOLOGY, 2010, 23 : 329A - 329A
12345